Understanding how specific proteins influence blood cell development
Official title: RUNX1-mediated regulation of MEP fate specification
Funded at Yale University · NIH-11081717 · Data updated 2026-11-12
This study looks at how a protein called RUNX1 helps decide whether certain blood cell precursors turn into platelets or red blood cells, and it aims to find new ways to help patients with acute myeloid leukemia (AML) by understanding these processes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $686,113 |
| NIH project number | 5R01DK139675-02 |
| Project ID | NIH-11081717 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals diagnosed with acute myeloid leukemia or related blood disorders.
✕Less likely to help
Patients with non-hematological conditions or those not diagnosed with blood cell disorders may not receive any benefit from this research.
What this research studies
This research investigates the molecular mechanisms that guide the development of blood cell progenitors, specifically focusing on how the RUNX1 protein affects the fate of megakaryocyte-erythroid progenitors (MEP). By examining how RUNX1 is modified by other proteins, the study aims to uncover how these changes influence whether these progenitors become platelets or red blood cells. Patients with acute myeloid leukemia (AML) may benefit from insights gained through this research, as it explores fundamental processes that could lead to new treatment strategies. The research employs advanced techniques in cell and molecular biology, along with proteomics, to analyze the behavior of these progenitor cells.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating acute myeloid leukemia and improving blood cell production.
How similar studies have gone: Previous research has shown promising results in understanding blood cell development, making this approach both relevant and potentially impactful.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Krause, Diane S — Yale University
- Study coordinator: Krause, Diane S
Related research
Other NIH-funded projects on the same topics.
-
Aging Well with HIV: Alcohol, Risk Reduction, and Education Center (AWAR3E)
A center at Yale is exploring how aging with HIV interacts with alcohol use to create inflammation and frailty, with the goal of finding biomarkers and potential treatments.
-
Community Health Worker–Led Hypertension Prevention and Control in Nepal
A community health worker–driven approach in Nepal aims to prevent and control high blood pressure among adults by bringing education and care directly to communities and homes.
-
Community health worker-led hypertension prevention and control in Nepal
A community health worker–led program in Nepal aims to help adults prevent and better control high blood pressure through home visits, education, and ongoing support.
-
Adapting a mobile health tool to boost HIV outcomes for older adults with HIV in Ukraine
A mobile health platform called PositiveLinks would be adapted for older adults with HIV in Ukraine to help them stay engaged in care and improve treatment success.
-
Behavioral and neural links between spoken language sounds and written words in young children
This grant studies how young children learn from listening and reading to improve literacy, by looking at how sound patterns transfer to written language.
-
Understanding how autoimmunity causes myasthenia gravis
This project looks at why the immune system attacks the nerve-muscle connection in myasthenia gravis and how different patient groups are affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.